期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

我如何治疗新诊断的年轻高危弥漫大B细胞淋巴瘤

How I treat newly diagnosed young patients with high risk diffuse large B cell lymphoma
原文传递
导出
摘要 弥漫大B细胞淋巴瘤（DLBCL）是一种高度异质性的恶性肿瘤。目前利妥昔单抗联合CHOP样方案的免疫化疗可使70％～85％的国际预后指数（IPI）评分低危患者获得长期生存及临床治愈；而对于IPI≥3分或一些特殊类型的高危DLBCL患者，R-CHOP方案治疗后患者的5年总体生存（0s）率远低于50％。
作者 邱录贵
机构地区 中国医学科学院、北京协和医学院血液学研究所、血液病医院 实验血液学国家重点实验室
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第9期747-750,共4页 Chinese Journal of Hematology
基金 基金项目：国家科技支撑计划（2014BAI09812）
关键词 弥漫大B细胞淋巴瘤 高危 治疗 CHOP方案 年轻 诊断 国际预后指数 利妥昔单抗
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Sehn LH, Berry B, Chhanabhai M, et al. The revised Internation- al Prognostic Index (R- IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R- CHOP [J ]. Blood, 2007, 109 (5): 1857- 1861.
  • 2Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced Interna- tional Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era [J]. Blood, 2014, 123(6): 837-842.
  • 3Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival [J ]. Blood, 2009, 114 ( 11 ): 2273-2279.
  • 4Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
  • 5Gang AO, Strom C, Pedersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B- cell lymphoma compared with R-CHOP- 14. A population-based investigation from the Danish Lymphoma Group [J]. Ann Oncol, 2012, 23( 1 ): 147-153.
  • 6Garcia-Sufirez J, Bafias H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study [J]. Br J Haematol, 2007, 136(2): 276-285.
  • 7Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximah in untreated diffuse large B-cell lymphoma with analysis of germinal center and post- germinal center biomarkers [J]. J Clin Oncol, 2008, 26 (16): 2717-2724.
  • 8Niitsu N, Kohri M, Hagiwara Y, et al. Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B- cell lymphoma [ J] Hematol Oncol, 2010, 28 (2): 68- 74.
  • 9Mato A, Feldman T, Zielonka T, et al. Rituximab, cyclophospha- mide-fractionated, vincristine, doxorubicin and dexamethasonealternating with rituximab, methotrexate and cytarabine over- comes risk features associated with inferior outcomes in treat- ment of newly diagnosed, high-risk diffuse large B-cell lympho- ma [J]. Leuk Lymphoma, 2013, 54 (12): 2606-2612.
  • 10Tilly It, Gomes dSM, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2015, 26 Suppl 5 :vl 16-125.

二级参考文献11

  • 1Martelli M,Ferreri AJ,Agostinelli C,et al.Diffuse large B-cell lymphoma[J].Crit Rev Oncol Hematol,2013,87(2):146-171.
  • 2Schmitz N,Nickelsen M,Ziepert M,et al.Conventional chemoimmunotherapy(R-CHOEP-14)or high-dose therapy(R-Mega-CHOEP)for young,high-risk patients with aggressive B-cell lymphoma:Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group(DSHNHL)[J].J Clin Oncol,2011,29(15):8002a.
  • 3Wilson WH,Dunleavy K,Pittaluga S,et al.Phase Ⅱ study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers[J].J Clin Oncol,2008,26(16):2717-2724.
  • 4Wilson WH,Jung SH,Porcu P,et al.A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype[J].Haematologica,2012,97(5):758-765.
  • 5Fayad L,Pro B,Hagemeister F,et al.R-HCVAD/R-MTX-ARAC is an effective regimen for untreated diffuse large B-cell lymphoma(DLBCL)with aggressive features in patients younger than 60 years[J].Blood,2007,110(11):1285a.
  • 6Mato A,Feldman T,Zielonka T,et al.Rituximab,cyclophosphamide-fractionated,vincristine,doxorubicin and dexamethasone alternating withrituximab,methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed,high-risk diffuse large B-cell lymphoma[J].Leuk Lymphoma,2013,54(12):2606-2612.
  • 7Fitoussi O,Belhadj K,Mounier N,et al.Survival impact of rituximab combined with ACVBP and upfront consolidation auto-transplantation in high-risk diffuse large B-cell lymphoma for GELA[J].Haematologica,2011,96(8):1136-1143.
  • 8Lee KW,Yi J,Choi IS,et al.Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement[J].Ann Hematol,2009,88(9):829-838.
  • 9Campbell J,Seymour JF,Matthews J,et al.The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement[J].Eur J Haematol,2006,76(6):473-480.
  • 10易树华,徐燕,邹德慧,安刚,赵耀中,齐军元,邱录贵.骨髓侵犯和不同治疗方案对弥漫大B细胞淋巴瘤患者预后的影响[J].中华血液学杂志,2009,30(5):307-312. 被引量：7

共引文献49

中华血液学杂志
2016年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部